NASDAQ:VTGN Vistagen Therapeutics (VTGN) Stock Price, News & Analysis $3.25 -0.01 (-0.31%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.24▼$3.3550-Day Range$3.18▼$3.9452-Week Range$2.45▼$7.10Volume43,280 shsAverage Volume192,846 shsMarket Capitalization$87.83 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vistagen Therapeutics alerts: Email Address Vistagen Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.33 Rating ScoreUpside/Downside315.4% Upside$13.50 Price TargetShort InterestBearish3.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.79) to ($1.85) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.46 out of 5 starsMedical Sector442nd out of 909 stocksPharmaceutical Preparations Industry199th out of 424 stocks 3.7 Analyst's Opinion Consensus RatingVistagen Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVistagen Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Vistagen Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.40% of the float of Vistagen Therapeutics has been sold short.Short Interest Ratio / Days to CoverVistagen Therapeutics has a short interest ratio ("days to cover") of 7.3.Change versus previous monthShort interest in Vistagen Therapeutics has recently increased by 8.19%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVistagen Therapeutics does not currently pay a dividend.Dividend GrowthVistagen Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTGN. Previous Next 3.3 News and Social Media Coverage News SentimentVistagen Therapeutics has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vistagen Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Vistagen Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vistagen Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.96% of the stock of Vistagen Therapeutics is held by insiders.Percentage Held by Institutions78.39% of the stock of Vistagen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vistagen Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vistagen Therapeutics are expected to decrease in the coming year, from ($1.79) to ($1.85) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vistagen Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vistagen Therapeutics is -1.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVistagen Therapeutics has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Vistagen Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. About Vistagen Therapeutics Stock (NASDAQ:VTGN)Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.Read More VTGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTGN Stock News HeadlinesSeptember 6 at 4:38 AM | finance.yahoo.comCompanies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In GrowthAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical TrialsSeptember 8, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…August 14, 2024 | msn.comBioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate ReportAugust 13, 2024 | seekingalpha.comVistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call TranscriptAugust 13, 2024 | markets.businessinsider.comVTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025August 13, 2024 | markets.businessinsider.comHere's what to expect from VistaGen Therapeutics's earningsAugust 13, 2024 | msn.comVistaGen Therapeutics Q1 2025 Earnings PreviewSeptember 8, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…July 26, 2024 | investorplace.com3 Stocks Under $15 That Could Make You a MillionaireJune 12, 2024 | gurufocus.comQ4 2024 Vistagen Therapeutics Inc Earnings Call TranscriptJune 12, 2024 | gurufocus.comVistagen Therapeutics Inc (VTGN) Q4 2024 Earnings Call Transcript Highlights: Significant ...June 11, 2024 | businesswire.comVistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateJune 7, 2024 | businesswire.comVistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024May 29, 2024 | businesswire.comVistagen to Present at the Jefferies Global Healthcare ConferenceMay 23, 2024 | businesswire.comVistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) ConferenceMay 14, 2024 | investorplace.com3 Must-Have Penny Stocks to Boost Your 2024 PortfolioMay 13, 2024 | investorplace.comMeme Stock Rebound: 3 Reddit Favorites Primed for a ResurgenceSee More Headlines Receive VTGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vistagen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/08/2024Next Earnings (Estimated)11/14/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VTGN CUSIPN/A CIK1411685 Webwww.vistagen.com Phone(650) 577-3600Fax888-482-2602Employees40Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+315.4%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,360,000.00 Net Margins-3,421.85% Pretax Margin-3,421.75% Return on Equity-35.12% Return on Assets-32.35% Debt Debt-to-Equity RatioN/A Current Ratio17.77 Quick Ratio17.77 Sales & Book Value Annual Sales$971,000.00 Price / Sales90.45 Cash FlowN/A Price / Cash FlowN/A Book Value$3.87 per share Price / Book0.84Miscellaneous Outstanding Shares27,025,000Free Float26,766,000Market Cap$87.83 million OptionableOptionable Beta0.80 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Shawn K. Singh J.D. (Age 61)CEO & Director Comp: $947.92kMs. Cynthia Lynn Anderson CPA (Age 55)Chief Financial Officer Comp: $391.2kMr. Joshua S. Prince M.B.A. (Age 53)Chief Operating Officer Comp: $568.44kMr. Reid G. Adler Esq. (Age 69)J.D., Chief Corporate Development Officer & General Counsel Comp: $675kMr. Mark Adrian McPartland (Age 58)Senior Vice President of Investor Relations Comp: $300kMs. Trisha FitzmauriceSenior Vice President of Human ResourcesDr. Allen Easley Cato IIIM.D., Ph.D., Senior Vice President of Development OperationsDr. Mark J. Ginski Ph.D. (Age 52)Senior VP and Head of Chemistry, Manufacturing & Controls Mr. Mark FlatherSenior Vice President of Corporate Strategy & Capital MarketsDr. Erik Berglund M.D.Ph.D., Senior VP of Global Regulatory Affairs & PharmacovigilanceMore ExecutivesKey CompetitorsProteostasis TherapeuticsNASDAQ:PTIMerrimack PharmaceuticalsNASDAQ:MACKOrganogenesisNASDAQ:ORGOSutro BiopharmaNASDAQ:STROLyell ImmunopharmaNASDAQ:LYELView All CompetitorsInstitutional OwnershipArmistice Capital LLCSold 64,000 shares on 8/15/2024Ownership: 1.109%Great Point Partners LLCSold 329,397 shares on 8/14/2024Ownership: 5.652%Blair William & Co. ILBought 20,000 shares on 8/12/2024Ownership: 0.327%Renaissance Technologies LLCSold 44,900 shares on 8/9/2024Ownership: 0.240%American Century Companies Inc.Bought 9,984 shares on 8/8/2024Ownership: 0.112%View All Institutional Transactions VTGN Stock Analysis - Frequently Asked Questions How have VTGN shares performed this year? Vistagen Therapeutics' stock was trading at $5.14 at the beginning of the year. Since then, VTGN stock has decreased by 36.8% and is now trading at $3.25. View the best growth stocks for 2024 here. How were Vistagen Therapeutics' earnings last quarter? Vistagen Therapeutics, Inc. (NASDAQ:VTGN) released its earnings results on Tuesday, August, 13th. The company reported ($0.35) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.06. The firm earned $0.08 million during the quarter, compared to analysts' expectations of $0.30 million. Vistagen Therapeutics had a negative net margin of 3,421.85% and a negative trailing twelve-month return on equity of 35.12%. When did Vistagen Therapeutics' stock split? Vistagen Therapeutics shares reverse split on Wednesday, June 7th 2023. The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Vistagen Therapeutics' major shareholders? Vistagen Therapeutics' top institutional shareholders include Great Point Partners LLC (5.65%), Armistice Capital LLC (1.11%), Blair William & Co. IL (0.33%) and Renaissance Technologies LLC (0.24%). Insiders that own company stock include Commodore Capital Lp, Venrock Healthcare Capital Par, Shawn Singh, Reid G Adler and Jerry B Gin. View institutional ownership trends. How do I buy shares of Vistagen Therapeutics? Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vistagen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vistagen Therapeutics investors own include Highpower International (HPJ), AK Steel (AKS), Ayala Pharmaceuticals (ADXS), Matinas BioPharma (MTNB), Rite Aid (RAD), Sorrento Therapeutics (SRNE) and Lithium Americas (LAC). This page (NASDAQ:VTGN) was last updated on 9/8/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
